1. Home
  2. PASG vs VRCA Comparison

PASG vs VRCA Comparison

Compare PASG & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PASG

Passage Bio Inc.

HOLD

Current Price

$15.11

Market Cap

28.6M

Sector

Health Care

ML Signal

HOLD

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$7.60

Market Cap

32.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PASG
VRCA
Founded
2017
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.6M
32.7M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
PASG
VRCA
Price
$15.11
$7.60
Analyst Decision
Strong Buy
Buy
Analyst Count
4
3
Target Price
$34.50
$17.00
AVG Volume (30 Days)
85.2K
185.1K
Earning Date
03-03-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$30,829,000.00
Revenue This Year
N/A
$373.20
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
234.73
52 Week Low
$5.12
$3.28
52 Week High
$20.00
$9.82

Technical Indicators

Market Signals
Indicator
PASG
VRCA
Relative Strength Index (RSI) 54.61 47.90
Support Level $13.33 $7.79
Resistance Level $20.00 $8.27
Average True Range (ATR) 2.12 0.60
MACD -0.02 -0.17
Stochastic Oscillator 47.32 7.24

Price Performance

Historical Comparison
PASG
VRCA

About PASG Passage Bio Inc.

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Share on Social Networks: